The Inaugural Barry L. Karger Medal Lectures and Award
Professor Matthias Mann, an outstanding scientist in the area of mass spectrometry and proteomics, was the inaugural recipient of the Barry L. Karger Medal in bioanalytical chemistry. Established by the friends and family Barnett Institute of Chemical & Biological Analysis at Northeastern University in honor of its founding director, the medal is a biennial award recognizing an individual who has significantly contributed to the development of new bioanalytical methods. Dr. Mann held the Inaugural Karger Medal Public Lecture on Thursday, October 15th in the Curry Student Center titled “How chromatography and mass spectrometry will shape tomorrow’s medicine” was well attended and a great success. This was followed by a dinner in Dr. Mann’s honor on Friday, October 16th; Dr. Mann delivered a research lecture titled “High Resolution LC MS/MS for cell signaling and biomedical research”
Dr. James Bean, Provost, Dr. Jon Tilly, Interim Dean College of Science; Dr. Matthias Mann, Karger Medal Recipient, Dr. Barry L. Karger, Director, Barnett institute
Dr. Barry L. Karger and Dr. Matthias Mann
“It is a great honor that Professor Matthias Mann was selected as the inaugural recipient of the Karger Medal. His outstanding research leads the way in the development and application of proteomics technology to basic biology and clinical sciences.” –Barry Karger
“I am greatly honored to receive the inaugural Barry L. Karger Award. Barry has been a great pioneer in our field for as long as I can remember, so I am overwhelmed by being the recipient of his award. Visiting Northeastern University has been a great pleasure, not the least because of all the exciting new technology developments going on here.” –Matthias Mann
Dr. Barry Karger, Director, Barnett Institute, Dr. Anthony Graffeo President, Graffeo and Associates and Dr. Steven Carr Director, of the Proteomics Platform, Broad Institute
James Bean, Provost and James L. Waters, founder Waters Corp.
Dr. Tom Trainor and David Heiger, Agilent Technologies, both Barnett Institute Alumni
Dr. Matthias Mann, presenting his award address
Barnett Institute/Department of Chemistry and Chemical Biology’s Entrepreneurship/Intrapreneurship Seminar Series
A very successful monthly seminar series began in January, 2015 on the topic entrepreneurship/intrapreneurship in the life sciences. Distinguished alumni and colleagues in pharma, biotech, medical devices and venture capital presented talks in this series. They discussed their careers and what it takes to be successful in start-up, small company and big pharma. Trends in the life sciences industry as well as how to overcome adversity were described. The series is very valuable to our students and staff.
Dan Levangie Co-founder and Managing Partner of ATON Partners, Daniel Levangie, an experienced executive with senior operating experience in the field of medical devices and in vitro diagnostics, is currently co-founder and Managing Partner of ATON Partners, a private investment and management consulting firm. Most recently Mr. Levangie was Chief Executive Officer of Dune Medical Devices and co-founder and Managing Partner of Constitution Medical Investors, Inc. (CMI) a Boston-based private investment and product development firm was acquired by Roche Diagnostics Corporation in July 2013.
Jonathan Flemming is the Managing Partner of Oxford Bioscience Partners. Bioscience Partners, an international venture capital firm specializing in life science technology based investments, with offices in Boston, Massachusetts and Seoul, Korea. He is a General Partner of the Korea-Seoul Life Science Fund. Mr. Fleming has been in the investment business for over twenty seven years, starting and financing growth companies in the United States, Europe, Israel and Asia. Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures in Boston, MA.
Jim Vath is the co-founder and current head of research and development for Zafgen Inc. Dr. Vath is the co-founder and current head of research and development for Zafgen, Inc., a local company working on novel approaches to obesity and metabolic diseases. Zafgen is a very successful virtual company that went public last year. The company is in Phase 3 trials of their lead candidate. Prior to Zafgen, Dr. Vath worked with established companies and new ventures to assess, develop and execute product and technology development plans. As senior vice president of product development at Phylogix Inc. a Boston-based start-up company working on oncology-supportive care, Dr. Vath created and implemented the corporate operational and R&D plan for the lead product.
Peter Barrett is a partner in the life sciences group at Atlas Venture. Dr. Peter Barrett is a partner in the life sciences group at Atlas Venture and focuses on investments in therapeutics and medical technologies that significantly change the medical management of patients. At Atlas, Peter has been involved in the creation of several novel therapeutic and drug discovery platform companies. He was instrumental in the sales of Stromedix to Biogen and Novamed to SciClone Pharmaceuticals. He is currently chairman of the boards of Harbour Antibodies, Raze Therapeutics, Synlogic, and Zafgen, and also serves on the boards of Mnemosyne Pharmaceuticals, InfaCare, JenaValve, and Vitae Pharmaceuticals.